Regulatory guide

Orphan drug designation in the US and EU: criteria, incentives and what changes in 2026

How orphan designation works at FDA and in the EU: prevalence thresholds, incentives such as 7 and 10 years of exclusivity, and the 2026 EU changes.

PharmaRadar360 Editorial · Published October 28, 2026 · 6 min read

Key points

Orphan designation is a status for a medicine in a specific rare disease. It is not an approval, and the medicine still needs full review.
US threshold: a disease affecting fewer than 200,000 people in the US. EU threshold: no more than 5 in 10,000 people in the EU.
US incentives include a tax credit for qualified clinical testing, exemption from user fees and potentially seven years of market exclusivity after approval.
EU incentives include protocol assistance, fee reductions and ten years of market exclusivity, which the 2026 pharma package reduces to a nine-year baseline once it applies.

What orphan designation is, and is not

Orphan designation recognises that a medicine is being developed for a rare disease and gives the sponsor incentives to continue. It is granted for a specific medicine in a specific condition, usually years before approval. FDA states plainly that designation is a separate process from approval, and that drugs for rare diseases go through the same scientific review as any other drug.

United States

The Orphan Drug Act of 1983 created the US program, which FDA’s Office of Orphan Products Development runs. A drug can be designated if the disease or condition affects fewer than 200,000 people in the United States, or if it affects more people but there is no reasonable expectation that US sales would recover the development cost.

Tax credit for qualified clinical testing costs (currently 25%, reduced from 50% by the 2017 tax law).
Exemption from FDA user fees.
Potentially seven years of market exclusivity after approval for the designated use.

European Union

In the EU, the Committee for Orphan Medicinal Products (COMP) at EMA reviews applications and the European Commission grants the designation. Three conditions apply: the disease is life-threatening or chronically debilitating; it affects no more than 5 in 10,000 people in the EU, or marketing would not generate enough return to justify the investment; and there is no satisfactory existing method of diagnosis, prevention or treatment, or the new medicine would be of significant benefit to those affected.

Designation is checked again at approval: the sponsor must apply to maintain it in order to receive market exclusivity, and the CHMP evaluates the medicine like any other.

Ten years of market exclusivity after authorisation under the current rules.
Protocol assistance, EMA’s scientific advice for designated orphan medicines.
Fee reductions, depending on the sponsor and the service.
Two additional years of exclusivity for orphan medicines that complete an agreed paediatric investigation plan.

Side by side

Orphan designation, US and EU
	United States (FDA)	European Union
Prevalence threshold	Fewer than 200,000 people in the US	No more than 5 in 10,000 people in the EU
Alternative route	Cost not expected to be recovered from US sales	Insufficient return on investment
Other conditions	None beyond the rare-disease test	Life-threatening or chronically debilitating; no satisfactory method, or significant benefit
Who decides	FDA Office of Orphan Products Development	European Commission, on the COMP’s opinion
Market exclusivity	Potentially 7 years	10 years today; 9-year baseline under the 2026 package

What the 2026 EU pharma package changes

Under the political agreement on the EU’s revised pharmaceutical legislation, the baseline orphan market exclusivity falls from ten to nine years, while “breakthrough” orphan medicines that address a condition with no existing EU treatment and show a clinically relevant reduction in mortality or morbidity can receive eleven years. The new rules apply 24 months after the legislation enters into force; until then the ten-year rule applies.

Reading orphan news

Designation announcements are early-stage news. Check the exact condition named: designation in one rare disease does not cover others.
In the EU, designations are listed in the Commission’s register of orphan medicinal products, and EMA publishes summaries of opinion.
Market exclusivity protects the designated indication. It does not stop the same company or others from developing different uses.

Sources

This guide is general information for professionals, written from the official sources listed above. It is not legal, regulatory or medical advice. Rules change: confirm details with the regulator before relying on them.